Advertisement

Topics

Clinical Trials About "revacept Thrombosis" RSS

18:39 EDT 16th October 2018 | BioPortfolio

We list hundreds of Clinical Trials about "revacept Thrombosis" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "revacept Thrombosis" on BioPortfolio

We have published hundreds of revacept Thrombosis news stories on BioPortfolio along with dozens of revacept Thrombosis Clinical Trials and PubMed Articles about revacept Thrombosis for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of revacept Thrombosis Companies in our database. You can also find out about relevant revacept Thrombosis Drugs and Medications on this site too.

Showing "revacept Thrombosis" Clinical Trials 1–25 of 656

Extremely Relevant

A Phase II Randomised Double-blind, Placebo-controlled Study of Revacept in Patients With Stable Coronary Artery Disease

The main objective is to evaluate the efficacy and safety of treatment with 2 doses (80 and 160 mg) of Revacept versus placebo in patients with stable coronary artery disease undergoing PCI.


Relevant

Safety, Pharmacokinetic and -Dynamic Study of PR-15, an Inhibitor of Platelet Adhesion

Primary objective: To evaluate safety and tolerability, adverse events (AEs), vital signs, ECG, bleeding time, evaluation of antibody titer and safety laboratory tests Secondary objectives: To evaluate the pharmacokinetics and pharmacodynamics (platelet aggregation)of six ascending single intravenous doses of PR-15 in healthy volunteers

Study on the Effect of Rosuvastatin Treatment on the Prevention of Thrombosis in Patients With Previous Thrombosis

This study evaluates whether treatment with rosuvastatin on top of standard anti-coagulant treatment will decrease the risk of recurrent venous thromboembolism and arterial thromboembolic events in patients with previous deep vein thrombosis or pulmonary embolism.


Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis.

Open randomized therapeutic study to assess the efficacy of Xarelto 15mg/day in the recurrence of thromboembolic event compared to an untreated group in patients with chronic portal vein thrombosis without high risk thrombophilia.

Daily Ultrasound-screening for CVC-related Thrombosis

The central venous catheters (CVC) related thrombosis is an issue of importance to ICU clinicians.This study conducts the daily ultrasound-screening for CVC-related thrombosis (DUCT).Its aim is to evaluate the characteristic and regularity of the central venous catheters (CVC) related thrombosis in ICU patients, and optimize the screening program of CVC-related thrombosis.

Rosuvastatin Use to Improve the Coagulation Profile in Patients With Venous Thrombosis

Epidemiological studies have shown a 2-3 fold increased long-term risk of arterial cardiovascular disease after venous thrombosis, most predominant in the first year following initial venous thrombosis. The results of recent observational studies that showed 40-50% risk reductions for first venous thrombosis occurrence when using a statin are in this aspect promising. The results are also somewhat surprising, because the mechanism behind this effect is unclear. Dyslipidemia may...

Treatment of Splanchnic Vein Thrombosis With Rivaroxaban. A Pilot, Prospective Cohort Study

Anticoagulant therapy is generally recommended for all patients presenting with acute symptomatic splanchnic vein thrombosis, starting with either low-molecular weight heparin (LMWH) or unfractionated heparin and continuing with the vitamin K antagonists in most patients. Rivaroxaban is approved for the treatment of deep vein thrombosis and pulmonary embolism, but no studies have assessed the safety of rivaroxaban in the setting of splanchnic vein thrombosis. We aim to collect ...

Stent Thrombosis After Tandem Lesions Thrombectomy

The aim is to describe the rate of delayed stent thrombosis after endovascular management of consecutive tandem lesions, in a patient series with systematic follow-up of stent patency. In addition, Investigatros aim to research baseline patient characteristics that are associated with a higher risk of delayed stent thrombosis and to evaluate the clinical consequences of stent thrombosis

Platelet Reactivity in Stent Thrombosis Patients

Recent studies have demonstrated a marked interindividual variability of clopidogrel's capacity to inhibit platelet aggregation with a substantial proportion (11-34%) of the patients considered non-responders to clopidogrel treatment. Variable intestinal absorption is suggested to contribute to the inconsistencies in response to clopidogrel. However, little is known about intestinal absorption in subjects who had suffered from a stent thrombosis. The MAPCAT-study has been desig...

Mesoglycan (Prisma®) Versus Placebo in Secondary Prevention of the Superficial Venous Thrombosis

The objective of the study is to demonstrate the superiority of the mesoglycan (Prisma®), compared to placebo, in reducing the incidence of thromboembolic complications (relapse / extension of superficial venous thrombosis (SVT), deep venous thrombosis (DVT), pulmonary embolism (PE)) in patients who have completed the cycle of therapy of the acute phase after superficial vein thrombosis.

Antiphospholipid Syndrome (APS) ACTION Plaquenil

The primary objective of this phase III study is to determine the efficacy of Hydroxychloroquine in the primary thrombosis prevention of persistently Antiphospholipid Antibody-(aPL)-positive but thrombosis free patients with no other systemic autoimmune diseases over the five year study period. Additionally, investigators are looking to determine thrombosis incident rate, the effect of Hydroxychloroquine on mortality rate and effect of Hydroxychloroquine on antiphospholipid ant...

Drug Eluting Stent Registry of Thrombosis

Multicenter, case-control study, to collect data regarding incidences of late and very late drug-eluting stent thrombosis with the aim of identifying trends and possible correlates of stent thrombosis.

Apixaban as Treatment of Venous Thrombosis in Patients With Cancer: The CAP Study

This study is a single-arm, phase IV trial, of apixaban as treatment of venous thrombosis in patients with cancer. The current standard treatment of venous thrombosis in cancer patients is subcutaneous injections with low molecular weight heparin. During the last 5 years several new direct acting oral anticoagulants have been tested out as treatment of venous thrombosis. But very few cancer patients were included in the phase III clinical trials of the direct acting oral antico...

Deep Venous Thrombosis After Hepatobiliopancreatic Surgery

To investigate the incidence of pre- and early postoperative deep venous thrombosis in patients undergoing hepatobiliopancreatic surgery, as well as potential corresponding risk factors with special attention to circulating tumor cells.

Usefulness of Anticoagulant Treatment in First Isolated Symptomatic Calf Vein Thrombosis

The CACTUS study is a 6-week evaluation of anticoagulant treatment effect on reducing infrapopliteal deep vein thrombosis (DVT) extension to proximal veins. Its aim is to demonstrate if the low molecular weight heparin (LMWH) use is really necessary for the treatment of a first infrapopliteal DVT episode, knowing the potential risks that their use induce.

Calf Deep Vein Thrombosis Treatment Trial

The primary objective is to evaluate whether apixaban is more effective in treating patients with isolated calf vein thrombosis (DVT) than serial imaging of the DVT for preventing thrombus spread, pulmonary embolism (PE) and/or recurring DVTs.

Upper Limb Thrombosis Associated With Midline Catheter

The patients admitted in hospital who had midline catheter inserted in upper limb are followed-up for the presence of complications related to catheter introductions. The symptoms and signs of upper limb thrombosis are recorded. The diagnosis is confirmed by sonography examination. In the selected group of asymptomatic patients sonography examination is done 8 to 10 days after cathether insertion in order to detect the incidence of the asymptomatic thrombosis

Residual Vein Thrombosis Establishes the Optimal Duration of Oral Anticoagulants

ABSTRACT Background The optimal duration of oral anticoagulant treatment in patients with idiopathic venous thromboembolism is still uncertain . The present study addressed the possible role of the Residual Vein Thrombosis in assessing the need for a prolonged anticoagulation. Methods Patients with a first episode of symptomatic unprovoked or provoked proximal Vein Thrombosis (VT) were given Oral Anticoagulant Treatment (OAT) for 3 months. Residual Vein Thrombosis (RVT),...

Prevention of Catheter-associated Thrombosis in Critically Ill Children

The purpose of this phase 2a, multi-center, single arm study, is to explore the efficacy of early prophylaxis against catheter-associated deep venous thrombosis (CADVT) in critically ill children.

Heparin and the Reduction of Thrombosis (HART) Trial

Heparin is frequently used in central venous catheters (CVCs) in post-operative cardiac patients. It remains unclear if a heparin infusion, compared to a normal saline infusion, prevents thrombosis of CVCs after surgery. This study will answer the question: does a low-dose heparin infusion (10 units/kg/h) prevent thrombosis, compared to a normal saline infusion, in patients less than one year of age after cardiac surgery?

Multi-Center Desirudin Utilization Trial in Patients With or Without Thrombosis Requiring an Alternative to Heparin-Based Anticoagulation

Demonstrate the clinical utility of fixed-dose SC Desirudin for the prophylaxis or treatment of thrombosis in patients in whom, in the opinion of the investigator, an alternative to heparin-based anticoagulation is desirable.

Factors Contribute to Very Late Stent Thrombosis After New Generation DES Implantation in China

We sought to identify and verify independent correlates of Very Late Stent Thrombosis after the implantation of new generation drug eluting steng in China from an analysis of multicenter registries.

Evaluation of Patients With Vena Cava Inferior Thrombosis

The purpose of the study is to evaluate patients with inferior vena cava (IVC)thrombosis in terms of etiology, clinical course and prognosis during long-term follow-up. Patients with isolated lower extremity DVT, matched for age and gender, serve as controls.

Cerebral Venous Sinus Thrombosis: Re-exploration of Clinical Assessment Scales

This is a single-center, retrospective, open-label study. This study is planned to investigate the accuracy of mRS and NIHSS, comparing with the accuracy of CSF pressure and papilledema grade in assessing cerebral venous sinus thrombosis.

Bedside Ultrasound in the Assessment of Deep Venous Thrombosis: Effectiveness of In-Person Versus Online Instruction

This study will examine the effectiveness of pre-recorded instructional videos in the use of bedside ultrasonography to ascertain the presence of a lower extremity deep venous thrombosis (DVT) as compared to in-person lectures and hands-on training.


More From BioPortfolio on "revacept Thrombosis"

Advertisement
Quick Search
Advertisement
Advertisement